Comparative Pharmacology
Head-to-head clinical analysis: MAXZIDE versus MAXZIDE 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAXZIDE versus MAXZIDE 25.
MAXZIDE vs MAXZIDE-25
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Maxzide is a combination of triamterene, a potassium-sparing diuretic that inhibits sodium reabsorption in the distal renal tubule, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule. The combination reduces electrolyte disturbances.
Maxzide-25 is a combination of hydrochlorothiazide, a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, and triamterene, a potassium-sparing diuretic that inhibits sodium reabsorption in the collecting duct by blocking epithelial sodium channels.
Hydrochlorothiazide 25 mg / triamterene 37.5 mg orally once daily; may increase to twice daily if needed. Max dose: hydrochlorothiazide 50 mg / triamterene 75 mg daily.
1 tablet (triamterene 37.5 mg/hydrochlorothiazide 25 mg) orally once daily.
None Documented
None Documented
Triamterene: terminal half-life is approximately 4-6 hours in healthy individuals, but may be prolonged in renal impairment. Hydrochlorothiazide: terminal half-life is approximately 6-15 hours, and it accumulates in renal dysfunction. The combination product's effective half-life is influenced by both components.
Triamterene: 2-4 hours (terminal half-life due to active metabolite hydroxylated triamterene, clinical effect persists 12-16 hours). Hydrochlorothiazide: 5.6-14.8 hours (mean 8.5 hours).
Renal: triamterene and hydrochlorothiazide are primarily excreted by the kidneys. Triamterene is extensively metabolized; about 20-30% of the dose is excreted unchanged in urine, with additional metabolites. Hydrochlorothiazide is excreted unchanged in urine (at least 61% of an oral dose within 24 hours).
Renal: triamterene 80-85% (as metabolites, 5-10% unchanged), hydrochlorothiazide ≥95% unchanged via tubular secretion; biliary/fecal: minimal (<5% each).
Category C
Category C
Diuretic Combination
Diuretic Combination